Outside review confirms top Memorial Sloan Kettering executives flouted conflicts-of-interest policies — report
The upper echelons of the Memorial Sloan Kettering (MSK) Cancer Center have been charged with cultivating a culture of putting profits before research and patients by persistently breaching conflict-of-interest policies in a review conducted by an independent body.
The results of the review — reported by the New York Times and ProPublica — solidifies a sweeping investigation by the two media organizations last year that found various top executives and board members from the leading New York-based cancer research and treatment center had profited from relationships with drugmakers, other research outfits and corporate board memberships.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.